Nuvation Bio Inc. Debt Securities, Available-for-sale, Unrealized Gain (Loss)
Nuvation Bio Inc. (NUVB) reported Debt Securities, Available-for-sale, Unrealized Gain (Loss) of -$139.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-29.
Discontinued › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss · last filed 2024-02-29
- Nuvation Bio Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2023-12-31 was $44.00K.
- Nuvation Bio Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2023-09-30 was $12.00K.
- Nuvation Bio Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2023-06-30 was -$99.00K.
- Nuvation Bio Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2023-03-31 was -$96.00K.
- Nuvation Bio Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2023 was -$139.00K.
- Nuvation Bio Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2022 was -$1.06M, a 1327.91% decline from fiscal 2021.
- Nuvation Bio Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2021 was $86.00K, a 60.55% decline from fiscal 2020.
- Nuvation Bio Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2020 was $218.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2023-12-31 | $44.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $56.00K derived: sum of 2 quarters · filed 2024-02-29 | -$43.00K derived: sum of 3 quarters · filed 2024-02-29 | -$139.00K 10-K · filed 2024-02-29 |
| 2023-09-30 | $12.00K 10-Q · filed 2023-11-02 | -$87.00K derived: sum of 2 quarters · filed 2023-11-02 | -$183.00K 10-Q · filed 2023-11-02 | -$311.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2023-06-30 | -$99.00K 10-Q · filed 2023-08-03 | -$195.00K 10-Q · filed 2023-08-03 | -$323.00K derived: sum of 3 quarters · filed 2024-02-29 | -$515.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2023-03-31 | -$96.00K 10-Q · filed 2023-05-04 | -$224.00K derived: sum of 2 quarters · filed 2024-02-29 | -$416.00K derived: sum of 3 quarters · filed 2024-02-29 | -$1.11M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-12-31 | -$128.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$320.00K derived: sum of 2 quarters · filed 2024-02-29 | -$1.01M derived: sum of 3 quarters · filed 2024-02-29 | -$1.06M 10-K · filed 2024-02-29 |
| 2022-09-30 | -$192.00K 10-Q · filed 2023-11-02 | -$885.00K derived: sum of 2 quarters · filed 2023-11-02 | -$928.00K 10-Q · filed 2023-11-02 | -$898.00K derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | -$693.00K 10-Q · filed 2023-08-03 | -$736.00K 10-Q · filed 2023-08-03 | -$706.00K derived: sum of 3 quarters · filed 2023-08-03 | -$696.00K derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$43.00K 10-Q · filed 2023-05-04 | -$13.00K derived: sum of 2 quarters · filed 2023-05-04 | -$3.00K derived: sum of 3 quarters · filed 2023-05-04 | -$2.00K derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $40.00K derived: sum of 2 quarters · filed 2023-03-15 | $41.00K derived: sum of 3 quarters · filed 2023-03-15 | $86.00K 10-K · filed 2023-03-15 |
| 2021-09-30 | $10.00K 10-Q · filed 2022-11-03 | $11.00K derived: sum of 2 quarters · filed 2022-11-03 | $56.00K 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $1.00K 10-Q · filed 2022-08-04 | $46.00K 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $45.00K 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | $218.00K 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |